Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference
NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD's sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022,…